Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Accumulated Expenses: 2022-2025

Historic Other Accumulated Expenses for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $4.8 million.

  • Phathom Pharmaceuticals' Other Accumulated Expenses rose 167.32% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 167.32%. This contributed to the annual value of $3.0 million for FY2024, which is 2501.71% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Other Accumulated Expenses of $4.8 million as of Q3 2025, which was down 1.60% from $4.9 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Other Accumulated Expenses ranged from a high of $4.9 million in Q2 2025 and a low of $20,000 during Q3 2023.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $897,000 (2024), whereas its average is $1.7 million.
  • Per our database at Business Quant, Phathom Pharmaceuticals' Other Accumulated Expenses crashed by 46.15% in 2023 and then skyrocketed by 8,865.00% in 2024.
  • Quarterly analysis of 4 years shows Phathom Pharmaceuticals' Other Accumulated Expenses stood at $151,000 in 2022, then dropped by 22.52% to $117,000 in 2023, then skyrocketed by 2,501.71% to $3.0 million in 2024, then soared by 167.32% to $4.8 million in 2025.
  • Its Other Accumulated Expenses stands at $4.8 million for Q3 2025, versus $4.9 million for Q2 2025 and $2.8 million for Q1 2025.